86.05

4.88% -5.0951

Rhythm Pharmaceuticals Inc (RYTM)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$91.15

Offen:

$88.84

24-Stunden-Volumen:

631.27K

Relative Volume:

0.82

Marktkapitalisierung:

$5.88B

Einnahmen:

$189.76M

Nettoeinkommen (Verlust:

$-196.54M

KGV:

-27.68

EPS:

-3.1087

Netto-Cashflow:

$-156.63M

1W Leistung:

-7.29%

1M Leistung:

-11.59%

6M Leistung:

-9.89%

1J Leistung:

+72.57%

1-Tages-Spanne:

$82.00

$90.50

1-Wochen-Bereich:

$82.00

$94.94

52-Wochen-Spanne:

$45.91

$122.20

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Firmenname

Rhythm Pharmaceuticals Inc

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

857-264-4280

Adresse

222 BERKELEY STREET, BOSTON, MA

Mitarbeiter

414

Twitter

@rhythmpharma

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

RYTM's Discussions on Twitter

Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RYTM Rhythm Pharmaceuticals Inc	86.04	6.22B	189.76M	-196.54M	-156.63M	-3.1087
VRTX Vertex Pharmaceuticals Inc	472.30	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	743.20	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	696.47	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	311.53	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.27	31.65B	5.36B	287.73M	924.18M	2.5229

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-19	Eingeleitet	RBC Capital Mkts	Outperform
2025-11-25	Eingeleitet	Citigroup	Buy
2025-11-05	Herabstufung	Oppenheimer	Outperform → Perform
2025-07-10	Eingeleitet	Goldman	Buy
2025-07-07	Eingeleitet	Leerink Partners	Outperform
2025-04-07	Hochstufung	BofA Securities	Neutral → Buy
2025-03-05	Fortgesetzt	Stifel	Buy
2025-01-02	Eingeleitet	Jefferies	Buy
2024-12-20	Eingeleitet	Oppenheimer	Outperform
2024-10-21	Eingeleitet	Guggenheim	Buy
2024-09-18	Eingeleitet	H.C. Wainwright	Buy
2024-09-17	Eingeleitet	JMP Securities	Mkt Outperform
2024-05-08	Herabstufung	BofA Securities	Buy → Neutral
2023-12-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-08-01	Hochstufung	BofA Securities	Neutral → Buy
2023-01-18	Fortgesetzt	Canaccord Genuity	Buy
2022-08-08	Hochstufung	Goldman	Neutral → Buy
2022-08-05	Hochstufung	BofA Securities	Underperform → Neutral
2022-06-17	Bestätigt	Needham	Buy
2022-03-02	Fortgesetzt	Stifel	Buy
2022-02-17	Hochstufung	Ladenburg Thalmann	Neutral → Buy
2021-12-08	Eingeleitet	Wells Fargo	Overweight
2021-11-19	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-09-14	Fortgesetzt	Goldman	Neutral
2021-08-04	Herabstufung	BofA Securities	Neutral → Underperform
2021-08-04	Herabstufung	Ladenburg Thalmann	Buy → Neutral
2020-11-30	Herabstufung	BofA Securities	Buy → Neutral
2020-01-08	Eingeleitet	Goldman	Sell
2019-07-12	Hochstufung	Stifel	Hold → Buy
2019-07-08	Eingeleitet	Canaccord Genuity	Buy
2019-03-13	Eingeleitet	Ladenburg Thalmann	Buy
2018-09-07	Fortgesetzt	Morgan Stanley	Overweight
2018-06-25	Bestätigt	Needham	Buy
2018-06-15	Bestätigt	Needham	Buy
2017-10-30	Eingeleitet	BofA/Merrill	Buy
2017-10-30	Eingeleitet	Needham	Buy

Alle ansehen

Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten

12:48 PM

Early FDA, Japan Filings For Setmelanotide In Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM) - simplywall.st

12:48 PM

Mar 12, 2026

Wells Fargo Maintains Overweight, Raises Price Target for RYTM t - GuruFocus

Mar 12, 2026

Wells Fargo raises Rhythm Pharmaceuticals price target on revenue - Investing.com

Mar 12, 2026

598,247 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Purchased by Capital Research Global Investors - MarketBeat

Mar 12, 2026

Mar 10, 2026

(RYTM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Mar 10, 2026

Mar 08, 2026

Rhenman & Partners Asset Management AB Purchases Shares of 35,000 Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat

Mar 08, 2026

Mar 06, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) CAO Sells $502,789.84 in Stock - MarketBeat

Mar 06, 2026

Rhythm Pharmaceuticals (RYTM) Is Down 8.2% After Positive TRANSCEND Data And FDA sNDA Progress - Sahm

Mar 06, 2026

Mar 05, 2026

Market Recap: Is Rhythm Pharmaceuticals Inc vulnerable to short sellers2025 Trade Ideas & Community Verified Watchlist Alerts - baoquankhu1.vn

Mar 05, 2026

Mar 04, 2026

Proposed sale of 64,540 common shares under registered plan (RYTM) - Stock Titan

Mar 04, 2026

HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat

Mar 04, 2026

Mar 03, 2026

Rhythm Pharmaceuticals (RYTM) CAO exercises RSUs, withholds shares for taxes - Stock Titan

Mar 03, 2026

Jefferies reiterates Rhythm Pharmaceuticals stock rating on trial outlook By Investing.com - Investing.com Canada

Mar 03, 2026

RYTM (NASDAQ: RYTM) brokered notice for 35,460-share sale on 03/03/2026 - Stock Titan

Mar 03, 2026

Does Rhythm Pharmaceuticals (RYTM) Share Price Reflect Its Obesity Treatment Potential Today - simplywall.st

Mar 03, 2026

Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright - Yahoo Finance

Mar 03, 2026

Mar 02, 2026

Rhythm Pharmaceuticals (RYTM) CFO exercises options, acquiring 6,099 shares - Stock Titan

Mar 02, 2026

Canaccord Genuity Lowers Price Target for RYTM, Maintains Buy Ra - GuruFocus

Mar 02, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $140.00 at Canaccord Genuity Group - MarketBeat

Mar 02, 2026

HC Wainwright Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $110.00 - MarketBeat

Mar 02, 2026

RYTM: HC Wainwright & Co. Lowers Price Target Despite Maintainin - GuruFocus

Mar 02, 2026

Why Is Rhythm Pharmaceuticals Stock Trading Higher Today?Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga

Mar 02, 2026